litlas
Log inCreate account

Guido Gerken

Active 1987–2022

134
Papers
25,798
Citations
94
h-index
134
i10-index

Citations

Citations per year for Guido Gerken1979: 1 citations1983: 1 citations1988: 1 citations1989: 3 citations1990: 5 citations1991: 5 citations1992: 20 citations1993: 30 citations1994: 42 citations1995: 37 citations1996: 33 citations1997: 41 citations1998: 49 citations1999: 65 citations2000: 79 citations2001: 119 citations2002: 114 citations2003: 111 citations2004: 128 citations2005: 151 citations2006: 160 citations2007: 163 citations2008: 183 citations2009: 173 citations2010: 205 citations2011: 208 citations2012: 233 citations2013: 252 citations2014: 264 citations2015: 273 citations2016: 239 citations2017: 249 citations2018: 217 citations2019: 716 citations2020: 802 citations2021: 783 citations2022: 614 citations2023: 425 citations2024: 539 citations2025: 269 citations2026: 6 citations1980–1982: no citations, so these years are not shown1984–1987: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,296 citing papers, 21% of this breakdownChina: 1,345 citing papers, 12.3% of this breakdownGermany: 934 citing papers, 8.6% of this breakdownItaly: 628 citing papers, 5.7% of this breakdownUnited Kingdom: 622 citing papers, 5.7% of this breakdownJapan: 487 citing papers, 4.5% of this breakdownFrance: 461 citing papers, 4.2% of this breakdownSpain: 368 citing papers, 3.4% of this breakdownCanada: 316 citing papers, 2.9% of this breakdownNetherlands: 285 citing papers, 2.6% of this breakdownAustralia: 273 citing papers, 2.5% of this breakdownSouth Korea: 241 citing papers, 2.2% of this breakdown
0%21%Other 24.4%

Institutions

Fields

  • Medicine71.6%
  • Biochemistry, Genetics and Molecular Biology14%
  • Immunology and Microbiology7.7%
  • Pharmacology, Toxicology and Pharmaceutics2.2%
  • Agricultural and Biological Sciences1.4%
  • Nursing0.8%
  • Other2.3%

Topics

  • Liver Disease Diagnosis and Treatment10%
  • Hepatocellular Carcinoma Treatment and Prognosis6.9%
  • Hepatitis B Virus Studies5.1%
  • Hepatitis C virus research4.6%
  • Liver Disease and Transplantation3.4%
  • Liver physiology and pathology2.6%
  • Other67.4%

Coauthors

All papers

Open in search
  1. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Eric Assénat, Giovanni Brandi, Marc Pracht, Ho Yeong Lim, Kun‐Ming Rau, Kenta Motomura, Izumi Ohno, Philippe Merle, Bruno Daniele, Dong Bok Shin, Guido Gerken, Christophe Borg, Jean‐Baptiste Hiriart, Takuji Okusaka, Manabu Morimoto, Yanzhi Hsu, Paolo Abada, Masatoshi Kudo - The Lancet Oncology 2019 cited by 1,655

  2. The interaction of hepatic lipid and glucose metabolism in liver diseases

    Authors: Lars P. Bechmann, Rebekka A. Hannivoort, Guido Gerken, Gökhan S. Hotamışlıgil, Michael Trauner, Ali Canbay - Journal of Hepatology 2011 cited by 991

  3. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis

    Authors: Jan Best, Lars P. Bechmann, Jan‐Peter Sowa, Svenja Sydor, Alexander Dechêne, Kristina Pflanz, Sotiria Bedreli, Clemens Schotten, Andreas Geier, Thomas Berg, Janett Fischer, Arndt Vogel, Heike Bantel, Arndt Weinmann, Jörn M. Schattenberg, Yvonne Huber, Henning Wege, Johann von Felden, Kornelius Schulze, Dominik Bettinger, Robert Thimme, Friedrich Sinner, Kerstin Schütte, Karl Heinz Weiss, Hidenori Toyoda, Satoshi Yasuda, Takashi Kumada, Sarah Berhane, Marc Wichert, Dominik Heider, Guido Gerken, Philip J. Johnson, Ali Canbay - Clinical Gastroenterology and Hepatology 2019 cited by 289

  4. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients

    Authors: Sarah Berhane, Hidenori Toyoda, Toshifumi Tada, Takashi Kumada, Chiaki Kagebayashi, Shinji Satomura, Nóra Schweitzer, Arndt Vogel, Michael P. Manns, Julia Benckert, Thomas Berg, Maria Ebker, Jan Best, Alexander Dechêne, Guido Gerken, JF Schlaak, Arndt Weinmann, Marcus A. Wörns, Peter R. Galle, Winnie Yeo, Frankie Mo, Stephen L. Chan, Helen L. Reeves, Trevor F. Cox, Philip J. Johnson - Clinical Gastroenterology and Hepatology 2016 cited by 323

  5. Toll-Like Receptor 2 Controls Mucosal Inflammation by Regulating Epithelial Barrier Function

    Authors: Elke Cario, Guido Gerken, Daniel K. Podolsky - Gastroenterology 2007 cited by 683

  6. Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC

    Authors: Svenja Sydor, Jan Best, I Messerschmidt, Paul Manka, Ramiro Vilchez‐Vargas, Susanne Brodesser, Christina Lucas, A Wegehaupt, C Wenning, S Aßmuth, Simon Hohenester, Alexander Link, Klaas Nico Faber, Han Moshage, Francisco Javier Cubero, Scott L. Friedman, Guido Gerken, Michael Trauner, Ali Canbay, Lars P. Bechmann - Clinical and Translational Gastroenterology 2020 cited by 131

  7. Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study

    Authors: Michael Bitzer, Marius Horger, Edoardo G. Giannini, Tom M. Ganten, Marcus A. Wörns, Jens T. Siveke, Matthias Dollinger, Guido Gerken, M. E. Scheulen, Henning Wege, Vittorina Zagonel, Umberto Cillo, Franco Trevisani, Armando Santoro, Vincenzo Montesarchio, Nisar P. Malek, Julia Holzapfel, Thomas Herz, Astrid Ammendola, Stefano Pegoraro, Bernhard Hauns, Anna Mais, Ulrich M. Lauer, Stefan Henning, Bernd Hentsch - Journal of Hepatology 2016 cited by 138

  8. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial

    Authors: Jordi Bruix, Jean‐Luc Raoul, Morris Sherman, Vincenzo Mazzaferro, Luigi Bolondi, Antonio Craxı̀, Peter R. Galle, Armando Santoro, Michel Beaugrand, Angelo Sangiovanni, Camillo Porta, Guido Gerken, Jorge A. Marrero, Andrea Nadel, Michael Shan, M. Moscovici, D. Voliotis, Josep M. Llovet - Journal of Hepatology 2012 cited by 821

  9. Effects of Fractionated Plasma Separation and Adsorption on Survival in Patients With Acute-on-Chronic Liver Failure

    Authors: Andreas Kribben, Guido Gerken, Sebastian Haag, Stefan Herget‐Rosenthal, Ulrich Treichel, Christoph Betz, Christoph Sarrazin, Eric A. J. Hoste, Hans Van Vlierberghe, Àngels Escorsell, Carsten Hafer, Oliver Schreiner, Peter R. Galle, Elena Mancini, Paolo Caraceni, Constantine Karvellas, Hermann Salmhofer, Mladen Knotek, Pere Ginès, Justyna Kozik–Jaromin, Kinan Rifai - Gastroenterology 2012 cited by 401

  10. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

    Authors: Harry L.A. Janssen, Monika van Zonneveld, Hakan Şentürk, Stefan Zeuzem, Ulus Salih Akarca, Yılmaz Çakaloğlu, Christopher Simon, Thomas M. K. So, Guido Gerken, Robert A. de Man, Hubert G.M. Niesters, Pieter E. Zondervan, Bettina E. Hansen, Solko W. Schalm - The Lancet 2005 cited by 1,163

  11. Non‐alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis

    Authors: Judith Ertle, Alexander Dechêne, Jan‐Peter Sowa, Volker Penndorf, Kerstin Herzer, Gernot Kaiser, JF Schlaak, Guido Gerken, Wing‐Kin Syn, Ali Canbay - International Journal of Cancer 2010 cited by 521

  12. Toll-like receptor 2 enhances ZO-1-associated intestinal epithelial barrier integrity via protein kinase C

    Authors: Elke Cario, Guido Gerken, Daniel K. Podolsky - Gastroenterology 2004 cited by 473

  13. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis

    Authors: Lars P. Bechmann, Peri Kocabayoglu, Jan‐Peter Sowa, Svenja Sydor, Jan Best, Martin Schlattjan, A Beilfuss, Johannes Schmitt, Rebekka A. Hannivoort, Alpaslan Kılıçarslan, Christian Rust, Frieder Berr, Oliver Tschopp, Guido Gerken, Scott L. Friedman, Andreas Geier, Ali Canbay - Hepatology 2013 cited by 231

  14. Small Bowel Homing T Cells Are Associated With Symptoms and Delayed Gastric Emptying in Functional Dyspepsia

    Authors: Tobias Liebregts, Birgit Adam, Christoph Bredack, Montri Gururatsakul, Katherine R. Pilkington, Stuart M. Brierley, L. Ashley Blackshaw, Guido Gerken, Nicholas J. Talley, Gerald Holtmann - The American Journal of Gastroenterology 2011 cited by 194

  15. Vitamin D counteracts fibrogenic TGF-β signalling in human hepatic stellate cells both receptor-dependently and independently

    Authors: A Beilfuss, Jan‐Peter Sowa, Svenja Sydor, Mechthild Beste, Lars P. Bechmann, Martin Schlattjan, Wing‐Kin Syn, Inga Wedemeyer, Zoltán Máthé, Christoph Jochum, Guido Gerken, Robert K. Gieseler, Ali Canbay - Gut 2014 cited by 155

  16. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

    Authors: Armando Santoro, Lorenza Rimassa, Ivan Borbath, Bruno Daniele, Stefania Salvagni, Jean‐Luc Van Laethem, Hans Van Vlierberghe, Jörg Trojan, Frank T. Kolligs, Alan Weiss, Steven A. Miles, Antonio Gasbarrini, Monica Lencioni, Luca Cicalese, Morris Sherman, Cesare Gridelli, Peter Buggisch, Guido Gerken, Roland M. Schmid, C. Boni, Nicola Personeni, Ziad Hassoun, Giovanni Abbadessa, Brian Schwartz, Reinhard von Roemeling, Maria Lamar, Yinpu Chen, Camillo Porta - The Lancet Oncology 2012 cited by 550

  17. In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?

    Authors: Amr El Fouly, Judith Ertle, Ahmed El Dorry, Mohamed Shaker, Alexander Dechêne, Heba Mohamed Abdella, Stefan Müeller, Eman Barakat, Thomas C. Lauenstein, Andreas Bockisch, Guido Gerken, JF Schlaak - Liver International 2014 cited by 125

  18. Radioembolization with Yttrium-90 Glass Microspheres in Hepatocellular Carcinoma: European Experience on Safety and Long-Term Survival

    Authors: Philip Hilgard, M Hamami, Amr El Fouly, André Scherag, Stefan Müller, Judith Ertle, Till A. Heusner, Vito R. Cicinnati, Andreas Paul, Andreas Bockisch, Guido Gerken, Gerald Antoch - Hepatology 2010 cited by 452

  19. Induction of cytokine production in naive CD4+ T cells by antigen-presenting murine liver sinusoidal endothelial cells but failure to induce differentiation toward Th1 cells☆, ☆☆

    Authors: Percy A. Knolle, Edgar Schmitt, Shu-Gen Jin, Tieno Germann, Rainer Duchmann, Silke Hegenbarth, Guido Gerken, AW Lohse - Gastroenterology 1999 cited by 299

  20. Toll‐like receptor‐induced innate immune responses in non‐parenchymal liver cells are cell type‐specific

    Authors: Jun Wu, Zhongji Meng, Min Jiang, Ejuan Zhang, Martin Trippler, Ruth Broering, Agnes Bucchi, Frank Krux, Ulf Dittmer, Dongliang Yang, Michael Roggendorf, Guido Gerken, Mengji Lu, JF Schlaak - Immunology 2009 cited by 210

  21. Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab

    Authors: Andrew X. Zhu, Richard S. Finn, Yoon‐Koo Kang, Chia-Jui Yen, Peter R. Galle, Josep M. Llovet, Eric Assénat, Giovanni Brandi, Kenta Motomura, Izumi Ohno, Bruno Daniele, Arndt Vogel, Tatsuya Yamashita, Chih‐Hung Hsu, Guido Gerken, John Bilbruck, Yanzhi Hsu, Kun Liang, Ryan C. Widau, Chunxiao Wang, Paolo Abada, Masatoshi Kudo - British Journal of Cancer 2021 cited by 66

  22. Hepatitis B virus suppresses toll-like receptor–mediated innate immune responses in murine parenchymal and nonparenchymal liver cells #

    Authors: Jun Wu, Zhongji Meng, Min Jiang, Rongjuan Pei, Martin Trippler, Ruth Broering, Agnes Bucchi, Jan‐Peter Sowa, Ulf Dittmer, Dongliang Yang, Michael Roggendorf, Guido Gerken, Mengji Lu, JF Schlaak - Hepatology 2008 cited by 315

  23. Development and functional consequences of LPS tolerance in sinusoidal endothelial cells of the liver

    Authors: A Uhrig, Ramin Banafsche, Michael Kremer, Silke Hegenbarth, Alf Hamann, Markus F. Neurath, Guido Gerken, Andreas Limmer, Percy A. Knolle - Journal of Leukocyte Biology 2005 cited by 164

  24. Human Kupffer cells secrete IL-10 in response to lipopolysaccharide (LPS) challenge

    Authors: P Knöll, JF Schlaak, A Uhrig, P. Kempf, Karl‐Hermann Meyer zum Büschenfelde, Guido Gerken - Journal of Hepatology 1995 cited by 381